A058820 Stock Overview
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CMG Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,110.00 |
| 52 Week High | ₩2,830.00 |
| 52 Week Low | ₩1,993.00 |
| Beta | 0.74 |
| 1 Month Change | -7.05% |
| 3 Month Change | -5.59% |
| 1 Year Change | -1.63% |
| 3 Year Change | -51.55% |
| 5 Year Change | -58.79% |
| Change since IPO | -7.46% |
Recent News & Updates
CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors
Mar 27
Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?
Dec 28Shareholder Returns
| A058820 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.9% | 0.5% | -0.4% |
| 1Y | -1.6% | 7.1% | 4.5% |
Return vs Industry: A058820 underperformed the KR Pharmaceuticals industry which returned 7.1% over the past year.
Return vs Market: A058820 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A058820 volatility | |
|---|---|
| A058820 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A058820 has not had significant price volatility in the past 3 months.
Volatility Over Time: A058820's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 265 | Joohyung Lee | www.cmgpharma.co.kr |
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd.
CMG Pharmaceutical Co., Ltd. Fundamentals Summary
| A058820 fundamental statistics | |
|---|---|
| Market cap | ₩293.06b |
| Earnings (TTM) | ₩6.46b |
| Revenue (TTM) | ₩93.91b |
45.4x
P/E Ratio3.1x
P/S RatioIs A058820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A058820 income statement (TTM) | |
|---|---|
| Revenue | ₩93.91b |
| Cost of Revenue | ₩50.31b |
| Gross Profit | ₩43.59b |
| Other Expenses | ₩37.14b |
| Earnings | ₩6.46b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 46.48 |
| Gross Margin | 46.42% |
| Net Profit Margin | 6.87% |
| Debt/Equity Ratio | 13.4% |
How did A058820 perform over the long term?
See historical performance and comparison